on behalf of GISSI-AF Investigators* Background-Left atrial (LA) dilation precedes or appears early after the onset of atrial fibrillation (AF) and factors in perpetuating the arrhythmia. Angiotensin receptor blockers were proposed for reversing LA remodeling. We evaluated the effect of valsartan on LA remodeling in patients with a recent episode of AF and the effect of LA size on AF recurrence (AFr). Methods and Results-LA and left ventricular (LV) echocardiographic variables were measured at baseline and 6 and 12 months in 340 patients from GISSI-AF, a trial testing valsartan prevention of AFr. Reversal of remodeling was considered as a decrease in LA size over 12 months. Changes in patients with and without recurrence and the relationship to duration of AFr were analyzed. Patients were 68.4Ϯ8.8 years old, with history of hypertension (85.3%) and cardioversion in the previous 2 weeks (87.4%) or Ն2 AFr in the previous 6 months (40.4%). Baseline LA maximal volume (LAVmax) was severely increased (Ͼ40 mL/m 2 ); LV dimensions and function were relatively normal. Over 12 months, 54.4% of patients had AFr. LAVmax was unchanged by rhythm, time, or randomized treatment. Higher baseline LAVmax and lower LA emptying fraction were linearly related to increasing AFr duration during follow-up. Conclusions-GISSI-AF patients in sinus rhythm and history of AF showed severely increased LAVmax with mostly normal LV volume, mass, and systolic and diastolic function. Valsartan for 1 year did not reverse LA remodeling or prevent AFr. Half of the patients without AFr had severe LA dilation; therefore, mechanisms other than structural remodeling triggered recurrence. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00376272. (Circ Cardiovasc Imaging. 2011;4:721-728.)
T he hypothesis that long-term renin-angiotensin system (RAS) inhibition could reverse the left atrial (LA) remodeling process and thereby contribute to the prevention of atrial fibrillation recurrence (AFr) was formally tested in the double-blind, randomized, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. 1, 2 The entirely neutral results of the study were somewhat surprising, 3 given the wealth of positive evidence. Data from experimental AF implicated RAS in the remodeling associated with atrial electric heterogeneity, ab-normal conduction, atrial hypertrophy and interstitial fibrosis. 4, 5 In contrast, RAS inhibitors attenuated the progression of atrial fibrosis, shortened AF duration, and improved LA function. 6 -8 Molecular studies of atrial samples in patients with persistent AF showed upregulated angiotensinconverting enzyme (ACE) and angiotensin II receptors that promoted structural and electric remodeling of the atrium. 9
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Post hoc analyses of clinical trials in patients with left ventricular dysfunction showed that ACE inhibitors and angiotensin receptor blockers (ARBs) reduced the onset of new AF, 10, 11 and, in prospective studies of patients after cardioversion of paroxysmal and persistent AF, RAS inhibitors in addition to amiodarone prevented recurrences of AF. 12 We report the results from the GISSI-AF echo study that explored whether the expected effect of valsartan to reverse LA remodeling would prevent AF recurrences. In addition, left atrial volume (LAV) and LV anatomy and function were assessed to estimate left ventricular resistance to LA emptying.
Methods
The GISSI-AF trial was a double-blind, randomized, placebocontrolled, multicenter study that enrolled 1442 patients in sinus rhythm with a history of AF to test whether the ARB valsartan could reduce the recurrence of AF (see Expanded Methods, Patients in the GISSI-AF Main Study, in the online-only Data Supplement). The primary end points were time to the first recurrence of AF and the proportion of patients who had more than 1 episode of AF over the 1-year observation period.
In the echocardiographic substudy, 340 patients (24% of the GISSI-AF population) were enrolled at 33 sites that were qualified by the central core laboratory to record echocardiograms according to a prespecified protocol (see Echocardiography section in the online-only Data Supplement). The study was approved by institutional review committees, and subjects gave informed consent.
Heart rate and blood pressure (BP) were measured before performing the echo exams. The recordings were acquired on CD or videotape and sent to the core laboratory for centralized reading with Medimatic software (Genova, Italy).
Centralized Reading
Measurements were repeated (3 times for sinus rhythm, 5 times for AF) and followed the American and European Societies of Echocardiography recommendations. 13 Atrial and ventricular chamber dimensions were indexed by body surface area. Because LA volumes calculated from the apical 2-and 4-chamber views (2APCH, 4APCH) resulted in similar values, 14 the reported LA volumes were measured from only 4APCH view, which was also the most consistently recorded and produced the most complete serial recordings. The within-reader reproducibility for left atrial maximal volume (LAVmax) was analyzed from the difference between duplicate measurements versus the mean measurement for each and calculated as the limits of agreement (mean difference Ϯ1.96 times SD). Reproducibility was also estimated from the measurement error as within-subject SD, expressed as repeatability (2.77 times measurement error). 15 Data from 50 randomly selected patients showed reproducibility for LAVmax as Ϫ0.03Ϯ1.98 mL and repeatability as 3.95 mL.
Detection of AF Recurrence
AF recurrence was detected by the transtelephonic transmission of ECG signals sent weekly, during symptomatic episodes, and during the follow-up visits to the primary physician and to the Coordinating Center. Each event was adjudicated blindly by a central reader and was verified by an ad hoc committee. 2
Statistical Methods
The effects of treatments were analyzed according to intention to treat. Continuous variables are expressed as meanϮSD or as medians [Q1-Q3] when required. Categorical variables are reported as absolute numbers and percentages. Differences between treatment groups in baseline characteristics were assessed by t test for continuous variables and by 2 test for categorical variables. Variables associated with time to first recurrence of AF were identified by univariate analysis and multivariable Cox proportional hazards models. The covariates age, sex, Ͼ2 episodes of AF in the 6 months before enrollment, and successful cardioversion in the 2 weeks before randomization were considered in the multivariable models. The prognostic value of each echocardiographic variable was evaluated separately. Changes of echocardiographic variables from baseline to 12-month follow-up were normally distributed; therefore analysis of covariance (ANCOVA) was used to evaluate differences in changes between valsartan and placebo groups after adjustment for their respective baseline values. For left atrial minimum volume (LAVmin) index and left atrial emptying fraction (LAEF), the model was further adjusted for LAVmax index, entered as a continuous variable.
LA volumes showed a nonnormal distribution, therefore a log transformation was applied.
Within-patient changes in LA volumes and LAEF over time for patients with and without AFr were compared by means of a repeated-measures ANOVA ("proc mixed"), in which AFr was considered according to its time of recurrence (0 -6 months and Ͼ6 -12 months). The total duration of AFr over 1 year was obtained by summing the number of days of each episode for each patient. A categorical variable was entered by tertiles of days of AF duration for patients with AFr and a separate category for patients without AFr.
The association between LA volumes at baseline and at 12 months with the total duration of AFr were evaluated by means of ANOVA, testing for trend across tertiles whenever statistically significant associations emerged. Differences in LA volumes and LAEF as least-squares means from baseline to 12 months by categories of duration of AF, adjusted for their respective baseline value, were tested using ANCOVA.
To determine the variables independently related to LAVmax Ͼ40 mL/m 2 , univariate and multivariable stepwise logistic regression analyses were performed, adjusting for Ն2 episodes of AF in the previous 6 months, cardioversion in previous 2 weeks from randomization, and duration of last qualifying episode of AF Ͼ7 days; heart failure, left ventricular ejection fraction (LVEF) Ͻ40%, or both; anticoagulants, amiodarone, statins, and aspirin as concomitant treatments; ECG LV hypertrophy; and hemoglobin.
All probability values were 2-tailed, and a value of Ͻ0.05 was considered statistically significant. The statistical analyses were done with SAS software (version 9.1).
Sample Size
The sample size calculation for the quantitative outcome was based on an expected absolute reduction of LAVmax of at least 6.7Ϯ20 mL (meanϮSD) between valsartan and placebo groups at 12 months. The number of patients per group required to have a power of 80% with a 2-sided ␣ error equal to 0.05, assuming a dropout rate of 30% (due to inadequate quality of echocardiograms and /or missing examinations), was calculated to be 200. 2
Results

Patient Data
The mean age of the 340 patients studied at baseline was 68.4Ϯ8.8 years (ϮSD), 36.2% were women, and 85.3% had been hypertensive for Ն6 months. The date of the first episode of AF in the patients clinical history was known in 262 of 340 (77%) of the subjects, and the median time between the onset of the arrhythmia to random assignment was 12 months (range, 6 days to 31 years). At least 2 episodes of AF in the previous 6 months were experienced by 40.4% of the patients, 87.4% were cardioverted in the previous 2 weeks, and in 39.7% the duration of the last episode was Ͼ7 days. There were no differences in baseline characteristics of the patients randomly assigned to valsartan or to placebo (Table 1) , except for the more common history of stroke in the treatment group (Pϭ0.03). Compared with the no-echo cohort (nϭ1102), patients enrolled in the echocardiographic substudy had higher prevalence of heart failure, LVEF Ͻ40% or both; peripheral artery disease; peripheral embolism; were more frequently current smokers; had higher heart rate; were more likely to have a QRS Ͼ120 ms; and were less often treated with ACE inhibitors (see additional Table in the online-only Data Supplement).
Echo Data
At baseline, mean LAVmax was severely increased: 43.1Ϯ15.0 mL/m 2 (normal LAVmax/BSA: Ͻ29 mL/ m 2 ). LA minimal volume was moderately increased: 23.4Ϯ12.3 mL/m 2 ; and LAEF was slightly to moderately depressed: 47.6Ϯ13.2%. LV end-systolic and end-diastolic volumes and ejection fraction were within normal ranges, whereas meanϮSD wall thickness was slightly increased (10.9Ϯ1.4 mm; normal for men: 6 -10 mm) and LV mass was normal (81.2Ϯ17.7 g/m 2 ; normal for men: 52-102 g/m 2 ). Although the mean values for Doppler mitral flow variables were normal, 36% of patients showed abnormal E/A, 28% and 48% with an abnormal DT and/or IVRT, respectively. In 128 of 340 patients with both, peak mitral E velocities and tissue Doppler mitral annular velocities the mean septal E/eЈ was 12.4Ϯ8.2 (normal: Յ8). Thirty-seven percent of patients had mild mitral regurgitation, 15.0% moderate, 3% severe, and 45% no regurgitation.
Echo Variables: Baseline and 12 Months by Treatment Group
None of the echo variables were affected by valsartan treatment from baseline to 12 months ( Table 2 ). These results were confirmed in a per-protocol analysis done in the 252 patients (88%) who took the study drug for at least 80% days of observation. The lack of effect of valsartan on LAVmin and on LAEF over time was found to be independent of baseline atrial dilation (covariate LAVmax, ANCOVA: Pϭ0.34 and 0.20, respectively).
To determine if LA volumes were influenced by the number of patients having recurrences of AF over time, patients in sinus rhythm at the end of the study (nϭ221) were analyzed separately and did not show any effect of treatment on LA dimensions and function (data not shown).
AF Recurrences
AF recurred in 54% of the patients during the 1-year follow-up. AF recurrence was associated with a history of Ն2 episodes of AF in the previous 6 months (Pϭ0.0004). The median number of recurrences per patient was 2 [1] [2] [3] [4] , with an overall median duration of 19.5 [4 -95] days over 12 months. Half of the AF recurrences took place within the first 2 months. Predictors of AFr were baseline LAVmin as increases in 1 mL/m 2 increments (hazard ratio, 1.02; 95% confidence interval [CI], 1.01-1.03; Pϭ0.003) and LAEF, as decreases in 1% units (hazard ratio, 1.02; 95% CI, 1.00 -1.03; Pϭ0.01). 
LA Volumes: With and Without AF Recurrences
LA volumes and LAEF according to rhythm and time are summarized in Table 3 for combined treatment groups. Baseline and 6-and 12-month data were available in 256 of 340 patients (75%). At baseline, patients without AFr and with early AFr (0 -6 months) had similar LAVmax that did not change significantly over time. Patients with late AFr (Ͼ6 -12 months) had smaller LAVmax compared with the other 2 groups, although differences were not statistically significant. Patients with early AFr (0 -6 months) tended to have larger LAVmin and smaller LAEF than the other 2 groups. Independent of AFr, LA function improved over 12 months (more evident in the first 6 months), as shown by a decrease in LAVmin (Pϭ0.04) and an increase in LAEF (Pϭ0.0001).
LA Volumes: Duration of AF Recurrence
LA variables in relation to the duration of AF recurrence are summarized in Table 4 and Figure 1 . 16 Patients with AFr were grouped into tertiles of number of days in recurrent AF over 1-year follow-up (T1: 1-6; T2: 7-58; T3: Ն59 days). Increasing days of AFr duration were linearly related to increasing baseline LA volumes (PϽ0.0001) and decreasing LAEF (PϽ0.0001). Of note, patients who remained in sinus rhythm had larger baseline volumes and lower LAEF than patients with the shortest AFr duration of 1-6 days. An analysis of patients with severely increased LAV (Ն40 mL/m 2 ) but without AFr showed a lower rate of Ն2 episodes of AF in the previous 6 months and fewer smokers than patients with Ն1 AFr (all PϽ0.05). Changes from baseline to 12 months across AF duration categories were not significant for LA volumes but resulted as statistically significant for LAEF ( Figure 2 ).
LA Maximal Volume: Associated Independent Variables
The independent factors associated with LAVmax Ն40 mL/m 2 were last qualifying episode of AF Ͼ7 days versus Յ7days (odds ratio, 4.16; 95% CI, 2.42-7.15; PϭϽ0.0001), ECG LV hypertrophy present versus absent (odds ratio, 4.65; 95% CI, 1.86 -11.62; Pϭ0.001), older age by 1 year (odds ratio, 1.03; 95% CI, 1.01-1.07; Pϭ0.01), and decreased hemoglobin by 1 g/dL (odds ratio, 1.26; 95% CI, 1.04 -1.51; Pϭ0.02).
Discussion
The findings of the GISSI-AF echo substudy were consistent with the main trial, which found that 320 mg daily of valsartan for 1 year did not reduce the incidence of recurrent AF. The substudy showed in addition that treatment had no effect on LA volumes and function in patients with or without AF recurrence. Earlier experimental evidence implicating the RAS in the LA remodeling process, 4, 5 and the reversal of the fibrosis and improvement in electric conduction and function with ARB and ACE inhibition, 6 -8 were supported by clinical studies that showed a significant reduction in recurrence of AF. 10 -12 Why did ARB treatment fail to reverse LA remodeling in GISSI-AF patients at high risk for AF recurrence with qualifying cardiovascular criteria?
The main trial revealed that of the 2 entry criteria, history of AF and at least 1 cardiovascular condition, 85% had only hypertension for Ն6 months as the other criteria (Table 1) . Thus, GISSI-AF patients were unlike those in successful ARB trials of preventing AF recurrence who were mainly in heart failure. 11 Only 10% of our patients had a positive history of heart failure or LVEF of Ͻ40%. The echocardiographic results further substantiated the absence of overt LV disease. LV ejection fraction was normal, as was LV end-diastolic volume and mass and Doppler variables of LV diastolic function. The only exceptions were the minimal increases in LV wall thickness and in E/eЈ ratio. Therefore, this apparent normality in LV structure and function may partly explain the lack of beneficial effects of the ARB valsartan.
LA remodeling or dilation appears to progress over time, depending on the underlying cardiovascular disease 17, 18 or on the arrhythmia itself. 19 Although LA volume reflects an average effect of LV filling pressures over time, 20, 21 the LA volumes were severely increased in the face of only minimal increase in LV wall thickness. On further analysis, 25-48% of patients exceeded the normal range of Doppler diastolic measurements and specifically 25% recorded a septal E/eЈ ratio Ն15, a value associated with increased LV filling pressures. 22 Nevertheless, with the majority of patients demonstrating normal LV volumes, mass, and standard filling velocities, AF itself appears to be the dominant mechanism for LA remodeling. 19 What were the quantitative consequences of recurrent AF alone on LA dilation? LA volumes were severely dilated to a mean of Ն40 mL/m 2 ; however, the degree of dilation is not unheard of, and similar LA volumes have been reported in small AF ablation studies. 23 Further findings of severe LA dilation were that the volumes were unalterable not only to ARB treatment but also unchangeable over time, independent of rhythm, intermittent sinus rhythm, and time to first AFr. Finally, with recurrent AF, the larger the LA volume, the more prolonged are the episodes of future AFr (Figure 2 ), a changing perspective on "AF begets AF through LA remodeling." The question this study raises: Is there LA remodeling beyond which there is no reversibility and inevitable progression of recurrent AF to chronic AF?
Perhaps of some encouragement, although LAVmax was unchanged, LA function did respond during the 1 year by significantly increasing LAEF and decreasing LAVmin (Table 3). A possible explanation is that 87% of the patients had been cardioverted within 2 weeks before random assignment. Parallel evidence from experimental AF demonstrated that loss of atrial contractility after cardioversion is followed by a partial or full functional recovery even though the amount of fibrosis persists. 24, 25 However, improvement in LA function in our study was limited (Table 4 and Figure 2 ) and did not occur in patients with the longest AFr duration of Ն59 days. The data again imply that there is a limit to LA dilation beyond which the atrium is no longer responsive to a pharmacological intervention or, less likely, that a longer exposure is necessary to achieve a therapeutic response. 3 The neutral results with ARB treatment on atrial remodeling, independent of the severely dilated LAVmax at baseline, offer little optimism for a trial of more prolonged ARB therapy.
The relation between LA volume and AF in patients with cardiovascular disease is complex, and few data are available regarding LA dimensions measured over time in such patients. 26, 27 The GISSI-AF patients were predominantly hypertensive with controlled BP (Table 2) , and, because hypertension is a significant risk factor for AF 28 and predictor of LA size, 18 our results suggest that any BP in the presence of recurrent AF is too high and should be treated, a hypothesis yet to be tested. 29 Prediction models showed that an increase of 10 mm Hg in BP, increased the risk of AF independent of age, sex, and ECG LV hypertrophy. 30 Belluzzi et al 31 credibly demonstrated that targeting systolic BP between 130 and 139 mm Hg with ramipril in patients with lone AF and normal LA and LV structures reduced the risk of AF recurrence. Initiating hypertensive treatment in patients with AF when systolic BP exceeds 120 mm Hg has been proposed, 29 in particular with anti-RAS therapies. 28 -32 Besides using LA size as a target organ for the aggressive treatment of BP in managing AF, the availability of newer drugs and procedures will also have to prove their effectiveness. Measuring LAVs will be central to selecting patients, tailoring treatment, and evaluating outcomes for this challenging rhythm.
Conclusions
In our study population, mainly hypertensive with severely dilated left atria, valsartan treatment for 1 year had no effect on reversing LA remodeling. LAVmax did not vary over time in patients with and without AF recurrence and pointed out that advanced atrial remodeling has a low probability of reversal. The degree of remodeling at baseline was strongly and linearly related to the duration of future AF recurrences and possibly affected the time to the first AF recurrence. Patients without recurrence also had severely enlarged LAVmax (Ͼ40 mL/m 2 ), indicating that mechanisms other than structural remodeling underlie recurring AF. Some of our incidental findings called attention to specific factors in AF mechanisms that underscored the need for further research in understanding AF pathogenesis.
